GT Biopharma Statistics
Total Valuation
GT Biopharma has a market cap or net worth of $5.78 million. The enterprise value is $1.83 million.
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025, after market close.
Earnings Date | May 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
GT Biopharma has 2.54 million shares outstanding. The number of shares has increased by 40.79% in one year.
Current Share Class | 2.54M |
Shares Outstanding | 2.54M |
Shares Change (YoY) | +40.79% |
Shares Change (QoQ) | +1.04% |
Owned by Insiders (%) | 15.69% |
Owned by Institutions (%) | 57.46% |
Float | 1.62M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | -3.46 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.72
Current Ratio | 0.72 |
Quick Ratio | 0.67 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -453.39% and return on invested capital (ROIC) is -306.19%.
Return on Equity (ROE) | -453.39% |
Return on Assets (ROA) | -97.90% |
Return on Invested Capital (ROIC) | -306.19% |
Return on Capital Employed (ROCE) | 860.12% |
Revenue Per Employee | n/a |
Profits Per Employee | -$13.16M |
Employee Count | 1 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.71% in the last 52 weeks. The beta is 1.32, so GT Biopharma's price volatility has been higher than the market average.
Beta (5Y) | 1.32 |
52-Week Price Change | -36.71% |
50-Day Moving Average | 2.31 |
200-Day Moving Average | 2.46 |
Relative Strength Index (RSI) | 49.47 |
Average Volume (20 Days) | 14,671 |
Short Selling Information
The latest short interest is 50,641, so 2.00% of the outstanding shares have been sold short.
Short Interest | 50,641 |
Short Previous Month | 72,301 |
Short % of Shares Out | 2.00% |
Short % of Float | 3.13% |
Short Ratio (days to cover) | 1.82 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -14.36M |
Pretax Income | -9.64M |
Net Income | -13.16M |
EBITDA | n/a |
EBIT | -14.36M |
Earnings Per Share (EPS) | -$6.94 |
Full Income Statement Balance Sheet
The company has $3.95 million in cash and n/a in debt, giving a net cash position of $3.95 million or $1.56 per share.
Cash & Cash Equivalents | 3.95M |
Total Debt | n/a |
Net Cash | 3.95M |
Net Cash Per Share | $1.56 |
Equity (Book Value) | -1.67M |
Book Value Per Share | -0.75 |
Working Capital | -1.67M |
Full Balance Sheet Cash Flow
Operating Cash Flow | -12.90M |
Capital Expenditures | n/a |
Free Cash Flow | -12.90M |
FCF Per Share | -$5.09 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
GT Biopharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -40.79% |
Shareholder Yield | n/a |
Earnings Yield | -227.60% |
FCF Yield | -223.14% |
Analyst Forecast
The average price target for GT Biopharma is $11.00, which is 376.19% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $11.00 |
Price Target Difference | 376.19% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
The last stock split was on February 5, 2024. It was a reverse split with a ratio of 0.0333333:1.
Last Split Date | Feb 5, 2024 |
Split Type | Reverse |
Split Ratio | 0.0333333:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |